D46.C Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality

Name of the Condition

• Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality

Summary

Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality is a subtype of myelodysplastic syndromes (MDS) characterized by low red blood cell counts (anemia) and a specific chromosomal abnormality where part of chromosome 5 is deleted. The condition is distinguished by the presence of this isolated deletion without other significant cytogenetic abnormalities. It typically affects older adults and may have a more favorable prognosis compared to other MDS subtypes.

Causes

The exact cause of this condition is often unknown. It involves genetic mutations, including the deletion of the long arm of chromosome 5 (del(5q)), which disrupts normal blood cell production. While the deletion is a key feature, the underlying mechanisms driving the development of this specific MDS subtype remain under investigation.

Risk Factors

• Age (most common in individuals over 60)
• Female gender (more prevalent in women)
• Prior exposure to chemotherapy or radiation therapy
• Family history of myelodysplastic syndromes or related blood disorders

Symptoms

• Fatigue or weakness due to anemia
• Pale skin
• Shortness of breath
• Dizziness or lightheadedness
• Mild to moderate cytopenias (low blood cell counts)

Diagnosis

Diagnosis involves a complete blood count (CBC) to identify anemia and other cytopenias, followed by a bone marrow biopsy to assess cell dysplasia. Cytogenetic analysis is critical to detect the isolated del(5q) chromosomal abnormality, which confirms the subtype. Additional tests may evaluate iron stores or rule out other causes of anemia.

Treatment Options

Treatment may include supportive care (e.g., blood transfusions, growth factors) to manage symptoms. For eligible patients, lenalidomide, a targeted therapy, is often used to improve anemia and reduce transfusion dependence. The choice of treatment depends on the patient’s age, overall health, and disease characteristics.

Prognosis and Follow-Up

Prognosis is generally more favorable than other MDS subtypes, with many patients experiencing stable disease or improved blood counts. Regular monitoring of blood counts and bone marrow status is essential to detect progression. Follow-up care focuses on managing symptoms and addressing any cytopenias.

Complications

• Progressive cytopenias (low blood cell counts)
• Increased risk of infections (due to low white blood cell counts)
• Potential progression to acute myeloid leukemia (AML) in rare cases
• Dependence on blood transfusions for anemia management

Lifestyle & Prevention

• Maintain a balanced diet to support overall health
• Avoid exposure to known environmental toxins (e.g., benzene)
• Practice good hygiene to reduce infection risk
• Follow up with healthcare providers for regular monitoring

When to Seek Professional Help

Seek medical attention if you experience persistent fatigue, unexplained bruising or bleeding, frequent infections, or shortness of breath. Early evaluation is important for timely diagnosis and management.

Tips for Medical Coders

Document the presence of the isolated del(5q) chromosomal abnormality to support the use of code D46.C. Ensure that cytogenetic testing results are clearly recorded, as this is a key diagnostic criterion. Avoid coding for other MDS subtypes or unrelated conditions without specific documentation.